All In Biotech

Drug Trial Radar · NCT04626518

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B in Second-Line Metastatic Participants

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 263 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

263

Actual

Start

Dec 17, 2020

Primary completion

Jul 23, 2026

Study completion Jul 23, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03B is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced second line plus (2L+) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • PembrolizumabBiological

    Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W

  • MK-4830Biological

    Administered via IV infusion at a dose of 800 mg Q3W

  • BelzutifanDrug

    Administered via oral tablet at a dose of 120 mg QD

  • LenvatinibDrug

    Administered via oral capsule at a dose of 20 mg QD

  • Pembrolizumab/QuavonlimabBiological

    Administered via IV infusion at a dose of 400 mg/25 mg Q6W

  • Favezelimab/PembrolizumabBiological

    Administered via IV infusion at a dose of 800 mg/200 mg Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Up to ~21 days
  2. Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)Time frame: Up to ~21 days
  3. Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to ~21 days
  4. Efficacy Phase: Number of participants who experienced DLTsTime frame: Up to ~21 days
  5. Efficacy Phase: Number of participants who experience one or more AEsTime frame: Up to ~56 months
  6. Efficacy Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to ~56 months
  7. Efficacy Phase: Objective response rate (ORR)Time frame: Up to ~56 months

Locations

51 sites in 13 countries. Site status is shown where the registry gives one.

  • University of California at San Francisco ( Site 3008)

    San Francisco, California

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 3011)

    New Haven, Connecticut

  • University of Chicago ( Site 3013)

    Chicago, Illinois

  • University of Iowa ( Site 3012)

    Iowa City, Iowa

  • Henry Ford Health System ( Site 3014)

    Detroit, Michigan

  • Laura and Isaac Perlmutter Cancer Center ( Site 3016)

    New York, New York

  • Memorial Sloan Kettering Cancer Center ( Site 3002)

    New York, New York

  • Duke Cancer Institute ( Site 3015)

    Durham, North Carolina

  • UPMC Cancer Center/Hillman Cancer Center ( Site 3017)

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center ( Site 3004)

    Nashville, Tennessee

  • UTSW Medical Center ( Site 3003)

    Dallas, Texas

  • Blacktown Hospital ( Site 3601)

    Blacktown, New South Wales, Australia

  • St George Hospital ( Site 3602)

    Kogarah, New South Wales, Australia

  • Royal Brisbane and Women's Hospital ( Site 3603)

    Herston, Queensland, Australia

  • Austin Health ( Site 3600)

    Melbourne, Victoria, Australia

  • Princess Margaret Cancer Centre ( Site 3101)

    Toronto, Ontario, Canada

  • Jewish General Hospital ( Site 3100)

    Montreal, Quebec, Canada

  • James Lind Centro de Investigacion del Cancer ( Site 4108)

    Temuco, Araucania, Chile

  • CIDO SpA-Oncology ( Site 4106)

    Temuco, Araucania, Chile

  • FALP-UIDO ( Site 4100)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill-Clinical Area ( Site 4101)

    Santiago, Region M. de Santiago, Chile

  • ONCOCENTRO APYS-ACEREY ( Site 4103)

    Viña del Mar, Valparaiso, Chile

  • Institut De Cancerologie De Lorraine ( Site 3204)

    Vandœuvre-lès-Nancy, Ain, France

  • Institut de cancérologie Strasbourg Europe (ICANS) ( Site 3203)

    Strasbourg, Alsace, France

  • Institut Claudius Regaud ( Site 3200)

    Toulouse, Haute-Garonne, France

  • Gustave Roussy ( Site 3202)

    Villejuif, Île-de-France Region, France

  • Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 4301)

    Budapest, Pest County, Hungary

  • Rambam Health Care Campus-Oncology Division ( Site 3500)

    Haifa, Israel

  • Hadassah Medical Center-Oncology ( Site 3504)

    Jerusalem, Israel

  • Rabin Medical Center ( Site 3502)

    Petah Tikva, Israel

  • Sheba Medical Center - Oncology Division ( Site 3501)

    Ramat Gan, Israel

  • Sourasky Medical Center ( Site 3503)

    Tel Aviv, Israel

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 4402)

    Amsterdam, North Holland, Netherlands

  • Erasmus Medisch Centrum ( Site 4401)

    Rotterdam, South Holland, Netherlands

  • Auckland City Hospital ( Site 3700)

    Auckland, New Zealand

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 4201)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 4200)

    Warsaw, Masovian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 4202)

    Gdansk, Pomeranian Voivodeship, Poland

  • Severance Hospital ( Site 3802)

    Seoul, South Korea

  • Samsung Medical Center ( Site 3801)

    Seoul, South Korea

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.